Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company...
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company...
Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a first...
Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a first...
CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of...
CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of...
Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical...
Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical...
Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at...
Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,...
LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of...
Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of...
– 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership – – Enrollment initiated...
- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy...
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small...
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million...
An Orphan Drug Designation Could Provide Significant Benefits to Regen SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma,...
Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, July 23, 2025 (GLOBE NEWSWIRE)...